Jan 30, 2025 09:06PM Canaccord Genuity Downgrades Intra-Cellular Therapies (ITCI) to Hold

Jan 29, 2025 09:12AM Cantor Fitzgerald provides update on Biotechnology stocks

Jan 27, 2025 05:17AM Intra-Cellular Therapies (ITCI) spreader of March 130 calls and May 135 calls

Jan 21, 2025 04:16PM RBC Capital Downgrades Intra-Cellular Therapies (ITCI) to Sector Perform

Jan 13, 2025 11:45PM Piper Sandler Downgrades Intra-Cellular Therapies (ITCI) to Neutral

Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA

Jan 13, 2025 09:54AM Morgan Stanley Downgrades Intra-Cellular Therapies (ITCI) to Equalweight

Jan 13, 2025 06:32AM Johnson & Johnson (JNJ) Acquires Intra-Cellular Therapies (ITCI) for $132/sh Cash or $14.6B

Jan 13, 2025 06:27AM J&J (JNJ) in Talks to Buy Intra-Cellular (ITCI) - Bloomberg

Jan 13, 2025 06:24AM Intra-Cellular Therapies (ITCI) PT Raised to $140 at Mizuho

Jan 10, 2025 02:36PM Intra-Cellular Therapies (ITCI) PT Raised to $118 at BofA Securities

Jan 2, 2025 01:02PM Piper Sandler Highlights NBIX, ITCI, ALKS, AXSM as High Conviction Ideas in Biotechnology

Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'

Dec 19, 2024 11:16AM RBC Capital's Game Changers: 'Disruptive Forces in Biotech'

Nov 29, 2024 06:32AM Mizuho Reiterates Outperform Rating on Intra-Cellular Therapies (ITCI)

Nov 5, 2024 07:00AM Intra-Cellular Therapies (ITCI) Reports Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA

Oct 30, 2024 04:38PM Intra-Cellular Therapies (ITCI) PT Raised to $79 at Goldman Sachs

Oct 30, 2024 07:32AM Intra-Cellular Therapies (ITCI) Misses Q3 EPS by 7c ; Offers Guidance

Sep 6, 2024 02:54AM Piper Sandler Upgrades Intra-Cellular Therapies (ITCI) to Overweight

Aug 21, 2024 06:21AM Intra-Cellular Therapies (ITCI) PT Raised to $81 at JPMorgan

Aug 8, 2024 06:23AM Intra-Cellular Therapies (ITCI) PT Lowered to $106 at RBC Capital

Aug 7, 2024 07:41AM Intra-Cellular Therapies (ITCI) Appoints Sanjeev Narula as CFO

Aug 7, 2024 07:35AM Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 3c ; Offers Guidance

Jul 30, 2024 07:17AM RBC's biotech survey shows investors more bearish vs. last time

Jul 23, 2024 07:25AM Intra-Cellular Therapies (ITCI) PT Raised to $79 at JPMorgan

Jul 22, 2024 07:43AM Intra-Cellular Therapies (ITCI) PT Raised to $100 at Needham

Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview

Jun 25, 2024 09:31AM UBS Downgrades Intra-Cellular Therapies (ITCI) to Neutral (earlier)

Jun 25, 2024 06:12AM RBC Capital Reiterates Outperform Rating on Intra-Cellular Therapies (ITCI), 'We remain buyers'

Jun 20, 2024 12:10PM Intra-Cellular Therapies (ITCI) PT Raised to $100 at Mizuho, 'Top Pick'

Jun 18, 2024 12:11PM Intra-Cellular Therapies (ITCI) PT Raised to $103 at RBC Capital

Jun 18, 2024 07:31AM Intra-Cellular Therapies (ITCI) Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Jun 10, 2024 05:38AM RBC Capital Reiterates Outperform Rating on Intra-Cellular Therapies (ITCI)

Feb 9, 2024 08:00PM 4 small and mid-cap biopharma stocks to own according to BofA